Characterization of deployment strategies.

M is a pre-specified constant, characterizing the relative use of drugs A and B in mixing phases (if not stated otherwise M = 0.5). () refers to the frequency of the strain resistant to A (B) among patients with a known resistance profile (i.e. patients in treatment class N). Thus, and . t is the current time point and tA (tB) the latest time-point at which resistance mutations against A (B) have been detected. In terms of the model described in Table 2, the time tA (tB) is given by the latest time-point at which an event of class 10 with y = A0 (y = 0B) has occurred.